Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in de novo schizophrenia patients
NCT04820309Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 400 days. Started Jun 2021; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04820309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820309.